Artificial Intelligence

A new partnership aims to revolutionize public safety with faster, smarter security screening. But can advanced AI balance security with personal privacy?

How a Japanese labor firm is leveraging traditional osteopathy and high-profile sports events to execute an ambitious global expansion strategy.

A new clinical trial in Malaysia could democratize advanced cancer care, testing an affordable, donor-derived immunotherapy challenging costly personalized treatments.

Enterprises lose up to 9% of revenue from missed contract obligations. New AI tools are turning static legal documents into actionable intelligence.

FBI data shows most active threats begin outdoors. New tech is extending security beyond the building, creating an integrated, automated defense.

Vyome's positive Phase 2 data targets a silent suffering in cancer care. This analysis explores its strategy to dominate a potential $1 billion market.

SAB Biotherapeutics' novel T1D therapy shows promise with a unique safety profile, challenging the status quo and offering new hope for patients.

EyeYon Medical's synthetic corneal implant, EndoArt, just got FDA approval for U.S. trials, offering a fix for the global donor tissue shortage.

A record-breaking tech award reveals a new map of global opportunity, data-driven trends, and a masterclass in strategic brand building from inDrive.

A new Solana meme coin is turning failure into a feature, offering tokens to traders for their verified losses. Is it a gimmick or the future of engagement?

Lumen Technologies is overhauling its balance sheet. Is this a savvy move for AI dominance or a risky gamble for the recovering telecom giant?

Newron launches a pivotal US trial for its novel schizophrenia drug, evenamide, aiming to help millions who don't respond to current treatments.

With a fresh $62M in funding, WELLSTAR is accelerating its AI and acquisition strategy ahead of a planned 2026 spinout, aiming to rewire Canadian healthcare.

New data reveals Syndax's Revuforj is a game-changer for leukemia, sparking a battle for market dominance in targeted cancer therapy.

The new SANY-Pony.ai autonomous truck is production-ready for 2026, promising to slash freight costs, boost profits, and redefine logistics.

How does a MedTech firm win 'Top Workplace' twice? Echosens proves that a mission-driven culture is the ultimate catalyst for innovation and market leadership.

A Swiss firm claims a CHF 480M raise and a $300M tech fund, but a closer look reveals a company with virtually no verifiable corporate footprint.

A breakthrough drug for a rare brain cancer sweeps prestigious international awards, offering patients a new, targeted therapy to delay aggressive treatments.

Bowman Consulting's acquisition of RPT Alliance is a strategic move to solve the energy crisis facing AI and data centers with rapid-deployment power.

New data shows Ascentage Pharma's drug achieves responses where a leading therapy fails, signaling a strategic coup in the high-stakes oncology market.